EA
AZN icon

Edge Advisors’s AstraZeneca AZN Stock Holding History

Edge Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$6K Buy
+93
New +$6.69K ﹤0.01% 737
2018
Q1 		– Sell
-75
Closed -$5K – 865
2017
Q4 		$5K Buy
+75
New +$5.06K ﹤0.01% 777
2017
Q2 		– Sell
-33
Closed -$2K – 926
2017
Q1 		$2K Hold
33
– – ﹤0.01% 863
2016
Q4 		$1K Buy
+33
New +$1.87K ﹤0.01% 800

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Edge Advisors's AZN Position: Q2 2018 in Review

Edge Advisors opened a new position in AstraZeneca (AZN) in Q2 2018: 93 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #737 among its holdings. This is a return to the name: Edge Advisors previously reported a position in AZN as recently as Q4 2017.

Edge Advisors first reported a position in AZN in Q4 2016 and has held it in 4 quarters since. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

  • Edge Advisors held 93 shares of AstraZeneca worth $6K as of Q2 2018.
  • AstraZeneca was a new Edge Advisors position in Q2 2018.
  • AstraZeneca made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #737 holding.
  • Edge Advisors first reported a position in AstraZeneca in Q4 2016 and has held it in 4 quarters since.
  • 530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.